Rossukon Kaewkhaw

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Venues

Journal of experimental & clinical cancer research : CR

Cancers

Molecular oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Atthapol Srimongkol, Natanan Laosillapacharoen, Duangporn Saengwimol, Vijender Chaitankar, Duangnate Rojanaporn, Thanastha Thanomchard, Suparerk Borwornpinyo, Suradej Hongeng, Rossukon Kaewkhaw
Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids. Journal of experimental & clinical cancer research : CR 42 (1) (2023)
Atthapol Srimongkol, Natanan Laosillapacharoen, Duangporn Saengwimol, Vijender Chaitankar, Duangnate Rojanaporn, Thanastha Thanomchard, Suparerk Borwornpinyo, Suradej Hongeng, Rossukon Kaewkhaw
Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids. Journal of experimental & clinical cancer research : CR 42 (1) (2023)
Pamorn Chittavanich, Duangporn Saengwimol, Sittiruk Roytrakul, Duangnate Rojanaporn, Vijender Chaitankar, Atthapol Srimongkol, Usanarat Anurathapan, Suradej Hongeng, Rossukon Kaewkhaw
Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression. Molecular oncology (2023)
Atthapol Srimongkol, Natanan Laosillapacharoen, Duangporn Saengwimol, Vijender Chaitankar, Duangnate Rojanaporn, Thanastha Thanomchard, Suparerk Borwornpinyo, Suradej Hongeng, Rossukon Kaewkhaw
Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids. Journal of experimental & clinical cancer research : CR 42 (1) (2023)
Rossukon Kaewkhaw, Duangnate Rojanaporn
Retinoblastoma: Etiology, Modeling, and Treatment. Cancers 12 (8) (2020)

Rossukon Kaewkhaw.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Rossukon Kaewkhaw